Clinical Trial Update: Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of zoledronic acid for hormone-sensitive bone metastases from prostate cancer has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-03-06